Edwards Lifesciences CORP DEF 14A proxy statements

Edwards Lifesciences issued a supplement to its proxy statement to clarify the treatment of abstentions and broker non-votes for the upcoming 2025 Annual Meeting of Stockholders.

Edwards Lifesciences' Spring 2025 stockholder presentation outlines the company's commitment to innovation, strategic growth drivers, and corporate governance.

Edwards Lifesciences Corporation will hold its annual meeting of stockholders on May 8, 2025, to vote on key proposals including the election of directors and executive compensation.

Edwards Lifesciences is asking stockholders to approve amendments to its employee stock purchase plans and highlights strategic steps taken to advance structural heart innovation.

Edwards Lifesciences emphasizes its focus on structural heart disease, innovation, and long-term shareholder returns in its Spring 2024 stockholder presentation.

Edwards Lifesciences Corporation will hold its annual meeting of stockholders on May 7, 2024, to vote on the election of directors, executive compensation, ratification of the accounting firm, and approval of the amended long-term stock incentive plan.

Edwards Lifesciences is undergoing a planned board transition, including the retirement of the current Chairman and a new independent Chairman appointment, alongside the nomination of a new director with extensive healthcare experience.